clinical trial · NCT05093933
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
Merck Sharp & Dohme LLC·phase3·completed·n = 6,106
Chronic Heart Failure With Reduced Ejection FractionVericiguatPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
started
Nov 2, 2021
primary completion
Nov 20, 2024
completion
Feb 5, 2025
last updated
Dec 19, 2025
official title
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol